L
Laverock Therapeutics
Developing a gene silencing platform for the creation of programmable, allogeneic cell therapies
About Laverock Therapeutics
Laverock Therapeutics is pioneering a unique gene silencing platform aimed at creating advanced programmable therapies. The company's innovative technology enhances the efficacy, safety, and accessibility of cell therapies by engineering novel functionalities that respond to both intra- and extracellular cues. This approach ensures directed and responsive activities, optimizing on and off-target profiles. Laverock's solutions are versatile, applicable across various therapeutic areas and cell types. The company collaborates with leading experts and research institutes to generate supportive data and initiate pre-clinical programs. Laverock's business model focuses on leveraging its proprietary computational and screening platforms to rapidly identify preferred genetic modifications and phenotypic outputs, facilitating the development of next-generation cell therapies. Revenue is generated through partnerships, licensing agreements, and potential commercialization of its therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 72.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery, Digital Pharma, DT and LS, rio ai health, rio AI health life sciences
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2026 | $2.9M | — | UK Research and Innovation | ↗ |
| GRANT✓Other financing | Oct 2025 | $658K | — | UK Research and Innovation | — |
Growth signals
Latest recorded traffic for Laverock Therapeutics is 370 monthly website visits, up 270% over the last three months. Laverock Therapeutics's team declined 12.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Laverock Therapeutics in the Stevenage ecosystem
The Laverock Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
Calculus Capital
Mercia Asset Management
Tekfen Ventures
Eos Advisory
Maven Capital Partners
Future Planet Capital
Eli Lilly
Mercia Ventures
Norcliffe Capital
UK Research and Innovation
Other known investors2 additional known investors
Grow London
Kris Kemeny
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Laverock Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Laverock Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









